New Antibody-conjugated Drugs Promise to Improve Bone Marrow Transplantation

1. New Antibody-conjugated Drugs Promise to Improve Bone Marrow Transplantation www.creative-biolabs.com/adc

2. Background Recently, Magenta Therapeutic, a cutting-edge company based in Cambridge, United States, announced that it has reached a patent license agreement with German biotechnology company Heidelberg Pharma to jointly develop antibody-conjugated drugs (ADCs) for improving pretreatment before bone marrow transplantation.

3. Bone marrow transplantation Bone marrow transplantation is hematopoietic stem cell transplantation. It is a treatment method for the treatment of a series of diseases by intravenous infusion of hematopoietic stem and progenitor cells to reconstruct the patient's normal hematopoietic and immune systems. Hematopoietic stem cell transplantation basically replaces the term “bone marrow transplantation” because hematopoietic stem cells are not only derived from bone marrow but also from peripheral blood that can be mobilized by hematopoietic factors. They can also be derived from cord blood to rebuild blood and immune system.

4. Magenta focused on improving stem cell transplantation. Its stem cell transplantation project has raised $98.5 million in funds. It has been favored by famous investors such as Google and established an authorized cooperation relationship with Novartis. At the same time, it attracted former Pfizer executives and drug development experts. Dr. John Davis joined the chief medical officer.

5. 1. The challenge of transplantation Pretreatment before stem cell transplantation is a big challenge. In order to reduce transplant rejection, patients must undergo “pretreatment” prior to receiving the transplant. The stem cells and diseased cells in the patient's bone marrow must be removed in advance to prevent transplanted stem cells from being rejected after entering the body. This process usually requires high-toxicity, high-dose radiotherapy, and there is a greater risk of toxicity and infection. Magenta scientists have discovered a variety of ADC drug, including antibody components that can specifically recognize stem cells and diseased cells, and target delivery of conjugated drugs to stem cells and diseased cells to specifically eliminate stem cells and pathologies. cell.

6. Conclusion 2. Targeted pretreatment programs are a significant medical requirement in the bone marrow transplantation field. This is where Magenta focuses its attention,” said Dr. Michael Cooke, Magenta's chief scientific officer. In the treatment project, we explored the discovery that Amanitin is a promising conjugated payload. Our cooperation with Heidelberg will allow us to fully evaluate the potential value of this class of antibody-conjugated drugs.

7. As a global company, we have more than 200 talented and well-trained scientists located in different continents working closely with partners from the entire world to develop and produce medicines of tomorrow. Specifically, we are the established leading expert in TCR and CAR T&NK cell immune therapy development, as we offer the one-stop custom services that cover the entire new drug development pipeline. Creative Biolabs

8. As a global company, we have more than 200 talented and well-trained scientists located in different continents working closely with partners from the entire world to develop and produce medicines of tomorrow. Specifically, we are the established leading expert in TCR and CAR T&NK cell immune therapy development, as we offer the one-stop custom services that cover the entire new drug development pipeline. Creative Biolabs

9. Contact Us 45-1 Ramsey Road, Shirley, NY 11967, USA Email: marketing@creative-biolabs.com

10. Thank you